Loading asset research
Q3 2026 earnings · Nov 5
Crescent Biopharma Inc. Common Stock
CBIONasdaq · USD · StocksQuote as of · Exchange session not verified$13.97
-1.90%
Today
CBIO
Loading 1D prices…
Market cap
$529M
Volume
228.7K
52w high
$27.4152w low
$8.72Company profile
Crescent Biopharma Inc. Common Stock
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Waltham, MA, United States
Employees
69
Fiscal year end
1231
CIK
1253689
Session & valuation
Open$14.29
Previous close$14.24
Day high$14.46
Day low$13.66
30-day avg. volume418.3K
Outstanding shares37.1M
Diluted EPS-$12.81
Latest annual period
P/E (trailing)-1.09
P/E (forward)-5.41
Price / book2.99
Beta—
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| DRUGBright Minds Biosciences Inc. Common Stock | $525M | — | — | -$1.78 | -3.20% | Buy |
| INDPIndaptus Therapeutics Inc. Common Stock | $533M | $0.00 | — | -$21.58 | -3.00% | Unrated |
| OCSOculis Holding AG Ordinary shares | $522.5M | — | — | -$1.89 | -1.49% | Buy |
| EOLSEvolus Inc. Common Stock | $519.2M | $297.2M | -17.38% | -$0.80 | +1.53% | Buy |
| EPRXEupraxia Pharmaceuticals Inc. Common Stock | $539.2M | $0.00 | — | -$1.03 | -1.84% | Buy |